Table 1.
Clinical drugs and pre-clinical compounds that activate pyroptosis in cancer cells
| Name of drug | Target protein | Gasdermin | Cell types | Daily use | Reference |
|---|---|---|---|---|---|
| Docosahexaenoic acid | NLRP3 | GSDMD | Breast cancer | Nutrient | 96,97 |
| Cisplatin | Caspase-3 | GSDME | Lung cancer, esophageal squamous cell carcinoma | Chemotherapy | 98,88 |
| Paclitaxel | Caspase-3 | GSDME | Lung cancer | Chemotherapy | 98 |
| As2O3 | NLRP1, 3 | GSDME | Hepatocellular carcinoma | Chemotherapy | 99 |
| Iron | Tom20 | GSDME | Melanoma | Anti-anemia | 100 |
| Doxorubicin | eEF-2K | GSDME | Melanoma | Chemotherapy | 101 |
| Pyridoxine | Caspase-3 | GSDME | leukemia | Nutrient | 102 |
| Lobaplatin | JNK | GSDME | Colon cancer | Chemotherapy | 103 |
| Metformin | PELP1 | GSDMD | Esophageal carcinoma | Anti-diabetes | 104 |
| Anthocyanin | NLRP3 | GSDMD | Oral squamous cell carcinoma | Nutrient | 105 |
| DPP 8/9 inhibitors | NLRP1, CARD8 | GSDMD | Leukemia | - | 106,107 |
| FL118 | NLRP3 | GSDMD | Colorectal cancer | - | 108 |
| α-NETA | Pro-caspase-4 | GSDMD | Epithelial ovarian cancer | - | 109 |
| L61H10 | Caspase-3 | GSDME | Lung cancer | - | 110 |
| Miltirone | MEK, ERK | GSDME | Hepatocellular carcinoma | - | 111 |